Delcath Systems (NASDAQ:DCTH) Stock Price Target Raised at HC Wainwright

Delcath Systems (NASDAQ:DCTH) had its price objective hoisted by research analysts at HC Wainwright from $32.00 to $36.00 in a note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the stock. HC Wainwright‘s price target indicates a potential upside of 77.60% from the company’s current price.

Several other equities analysts also recently issued reports on DCTH. Zacks Research downgraded shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. Wall Street Zen upgraded Delcath Systems from a “hold” rating to a “buy” rating in a research report on Saturday, August 8th. BTIG Research increased their price objective on Delcath Systems from $21.00 to $25.00 and gave the stock a “buy” rating in a report on Monday. Finally, Weiss Ratings cut Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a research report on Wednesday, October 28th. Two investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $29.33.

Delcath Systems Price Performance

DCTH stock opened at $20.27 on Tuesday. Delcath Systems has a 1-year low of $8.12 and a 1-year high of $20.30. The firm has a fifty day moving average price of $15.53 and a two-hundred day moving average price of $12.49. The firm has a market cap of $703.37 million, a price-to-earnings ratio of 2,029.03 and a beta of 0.62.

Delcath Systems (NASDAQ:DCTH) last issued its earnings results on Monday, November 9th. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.26. Delcath Systems had a net margin of 0.56% and a return on equity of 0.46%. The company had revenue of $35.10 million for the quarter, compared to analysts’ expectations of $25.99 million. As a group, analysts expect that Delcath Systems will post -0.17 EPS for the current fiscal year.

Institutional Trading of Delcath Systems

A number of institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp bought a new position in shares of Delcath Systems in the second quarter valued at approximately $1,362,000. Allspring Global Investments Holdings LLC acquired a new position in shares of Delcath Systems during the first quarter valued at approximately $306,000. Kopp Family Office LLC bought a new stake in Delcath Systems during the third quarter worth approximately $450,000. Sei Investments Co. raised its holdings in Delcath Systems by 100.0% during the first quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock worth $409,000 after purchasing an additional 22,029 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in Delcath Systems by 31.1% in the third quarter. Russell Investments Group Ltd. now owns 88,727 shares of the company’s stock worth $1,417,000 after purchasing an additional 21,069 shares during the period. 61.12% of the stock is owned by institutional investors and hedge funds.

Delcath Systems News Summary

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: Q3 earnings were $0.17 per share, versus analysts’ expected loss of $0.09, and revenue of $35.1 million exceeded the $26.0 million consensus estimate. Zacks earnings report
• Positive Sentiment: Delcath guided to $115 million–$117 million in 2026 revenue, above the $106.2 million analyst consensus, and said it is targeting at least 36 active centers by year-end. The higher outlook and expansion target point to stronger expected commercial performance. 2026 guidance and active-center target
• Positive Sentiment: BTIG Research raised its price target to $25 from $21 and reiterated a Buy rating, reflecting a more bullish analyst view. BTIG Research rating information

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.